Abstract Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has undergone
multiple mutations since its emergence, and its latest variant, Omicron (B. 1.1. 529), is the …

Since early 2020, the world has been embroiled in an ongoing viral pandemic with SARS‐
CoV‐2 and emerging variants resulting in mass morbidity and an estimated 6 million deaths …

Summary Background By June 30, 2022, 92· 6% of the Chilean population older than 18
years had received a full primary SARS-CoV-2 vaccine series, mostly with CoronaVac …

Background In view of limited evidence that specifically addresses vaccine effectiveness
(VE) in the older population, this study aims to evaluate the real-world effectiveness of …

Introduction Inactivated vaccines were delivered to low-and middle-income countries during
the early pandemics of COVID-19. Currently, more than 10 inactivated COVID-19 vaccines …

Introduction of primary COVID-19 vaccination has helped reduce severe disease and death
caused by SARS-CoV-2 infection. Understanding the protection conferred by heterologous …

Background: The ongoing COVID-19 pandemic has posed increased risks of hospitalization
and mortality in patients with underlying chronic kidney disease (CKD). Current data on …

Background The inactivated virus vaccine, BBIBP-CorV, was principally distributed across
low-and middle-income countries as primary vaccination strategy to prevent poor COVID-19 …

The SARS-CoV-2 Omicron variant and its sublineages continue to cause COVID-19-
associated pediatric hospitalizations, severe disease, and death globally. BNT162b2 and …

Introduction: Although the adaptive immune responses to the CoronaVac vaccine are
known, their dynamics in indigenous communities remain unclear. In this study, we …